PET/MRI/EEG Imaging Study in Epilepsy

Massachusetts General Hospital30 enrolled

Overview

This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]). The study will also compare how the three imaging modalities localize regions of abnormal function in the brain.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Epilepsy

Interventions

FDG-PET/fMRI/EEG imagingRADIATION

Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 or older Additional Inclusion Criteria for Subjects with Epilepsy: * Diagnosed with epilepsy with abnormal interictal EEG Exclusion Criteria: * Contraindications to PET, MRI, or EEG imaging * History of severe brain disease such as stroke and head trauma * History of brain surgery * History of type I or II diabetes mellitus * Fasting plasma glucose level \>200 mg/dL * Employed under direct supervision of the PI conducting the research Additional Exclusion Criteria for Healthy Subjects: * Current use of drugs that modulate brain function * Current or past history of major medical, neurological, or psychiatric conditions

Locations (1)

Athinoula A. Martinos Center

Charlestown, Massachusetts, United States

RECRUITING

Outcomes

Primary Outcomes

Image analysis

There are no interventions in this study and thus no outcome measures. Primary goal of the study will be achieved with image analysis on the PET/MRI/EEG data.

Time frame: Image analysis to be performed after imaging sessions are complete.

Central Contacts

Magdelena S Allen, BA

CONTACT

617-724-9232 mallen27@mgh.harvard.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.